Cameron Turtle

Chief Executive Officer at SPYRE THERAPEUTICS, INC.

Net worth: 48 M $ as of 2026-05-30

36 year

11 connections

Health Technology

Consumer Services

Electronic Technology

Profile

Cameron Turtle is currently Chief Executive Officer & Director at Spyre Therapeutics, Inc. since 2023.
Dr. Turtle is also Director at CoA Therapeutics, Inc. since 2018, Director at Fortify Therapeutics, Inc. since 2017, Director at Dermecular Therapeutics, Inc. since 2017, Director at Aspa Therapeutics, Inc. since 2018, and Independent Director at Damora Therapeutics, Inc. starting in 2026.
Former roles include Independent Director at Oruka Therapeutics, Inc. from 2024 to 2025, Chief Business Officer at Eidos Therapeutics, Inc. from 2018 to 2021, VP-Business Development & Operations at Navire Pharma, Inc. from 2017 to 2018, Venture Partner at Foresite Labs LLC from 2022 to 2023, and Chief Strategy Officer at BridgeBio Pharma, Inc. from 2021 to 2022.
Education includes undergraduate studies at the University of Washington and a doctorate from St. John's College.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
SPYRE THERAPEUTICS, INC 0.67%	2026-06-30	582,540 ( 0.67% )	43 M $	2026-05-30
0.18%	2025-06-01	85,233 ( 0.18% )	5 M $	2026-05-30

Cameron Turtle active positions

Companies	Position	Start
SPYRE THERAPEUTICS, INC.	Chief Executive Officer	2023-11-26
DAMORA THERAPEUTICS, INC.	Director/Board Member	2026-03-22
Aspa Therapeutics, Inc. Aspa Therapeutics, Inc. Aerospace & DefenseElectronic Technology Part of BridgeBio Pharma, Inc., Aspa Therapeutics, Inc. is a biotechnology company focused on developing gene therapy for Canavan disease, a rare genetic leukodystrophy caused by mutations in the ASPA gene. The company is based in San Francisco, CA. The disease leads to toxic accumulation of N-acetyl-L-aspartic acid in the brain, resulting in demyelination and severe neurological impairment. Aspa Therapeutics is conducting the CanAspire clinical trial to evaluate an adeno-associated virus (AAV) gene therapy designed to deliver functional ASPA genes to the brain and address the root cause of the disease. The therapy was developed in collaboration with the University of Massachusetts Medical School. The company collaborates with patient advocacy organizations and provides resources and updates to patients and families.	Director/Board Member	2018-05-31
CoA Therapeutics, Inc. CoA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals	Director/Board Member	2017-12-31
Dermecular Therapeutics, Inc.	Director/Board Member	2017-06-30
Fortify Therapeutics, Inc. Fortify Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals	Director/Board Member	2017-11-30

All active positions of Cameron Turtle

Former positions of Cameron Turtle

Companies	Position	End
Foresite Labs LLC Foresite Labs LLC Miscellaneous Commercial ServicesCommercial Services Provides incubation platform services	Corporate Officer/Principal	2023-04-30
BRIDGEBIO PHARMA, INC.	Corporate Officer/Principal	2022-03-31
Navire Pharma, Inc. Navire Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals	Chief Operating Officer	2018-02-28
░░░░░ ░░░░░░░░░░░░░ ░░░░	░░░░░░░░░░░░░░ ░░░░░░	-

See the detail of Cameron Turtle's experience

Training of Cameron Turtle

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Cameron Turtle's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	12
Spyre Therapeutics, Inc. Spyre Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biotechnology company	Health Technology
University of Washington University of Washington Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
St. John's College St. John's College Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Eidos Therapeutics, Inc. Eidos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company	Health Technology
Navire Pharma, Inc. Navire Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals	Health Technology
CoA Therapeutics, Inc. CoA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals	Health Technology
Fortify Therapeutics, Inc. Fortify Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals	Health Technology
BridgeBio Pharma, Inc. BridgeBio Pharma, Inc. BiotechnologyHealth Technology Develops medicines for genetic diseases to patients	Health Technology
Galecto, Inc. Galecto, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of severe diseases	Health Technology
Dermecular Therapeutics, Inc.
Aspa Therapeutics, Inc. Aspa Therapeutics, Inc. Aerospace & DefenseElectronic Technology Part of BridgeBio Pharma, Inc., Aspa Therapeutics, Inc. is a biotechnology company focused on developing gene therapy for Canavan disease, a rare genetic leukodystrophy caused by mutations in the ASPA gene. The company is based in San Francisco, CA. The disease leads to toxic accumulation of N-acetyl-L-aspartic acid in the brain, resulting in demyelination and severe neurological impairment. Aspa Therapeutics is conducting the CanAspire clinical trial to evaluate an adeno-associated virus (AAV) gene therapy designed to deliver functional ASPA genes to the brain and address the root cause of the disease. The therapy was developed in collaboration with the University of Massachusetts Medical School. The company collaborates with patient advocacy organizations and provides resources and updates to patients and families.	Electronic Technology
Foresite Labs LLC Foresite Labs LLC Miscellaneous Commercial ServicesCommercial Services Provides incubation platform services	Commercial Services